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Background: Biomarkers that predict the rate of HIV disease
rogression in HIV-infected children might assist in clinical deci-
ions of when to start ARV among children with mild to moderate
mmune suppression.
Methods: This is a substudy of the PREDICT study, a random-
zed trial of immediate versus deferred antiretroviral initiation in
hildren aged 1-12 years in Thailand and Cambodia. HIV-infected
hildren with CD4 15-24% had CD4 monitoring every 12 weeks and
tarted ART when CD4<15%. Long term non progressors (LTNP)
ere deﬁned as age>8 years anytime during the study with
D4>15%, slow progressors were <8 years with CD4>15% at the
tudy end, and routine progressors had CD4 decline to <15% before
ge 8 years. BaselineHIV RNA, soluble CD14 (sCD14) and C-reactive
rotein (CRP) were measured and multinomial logistic regression
as performed to discern relative risk (RR) ratios of disease pro-
ression for each biomarker with LTNP as a reference group.
Results: There were 147 HIV-infected children with mean age
f 6.5 years, %CD4 of 20.6, plasma HIV RNA of 4.6 log10 copies/ml.
here were 85,25 and,37 children in LTNP, slow and routine pro-
ressor groups, respectively. Inmultivariatemodels, the RR (95%CI)
f being a slow progressor for children with baseline viral load ≥
log10 copies/ml was 6.0 (1.9-18.6; p =0.002) after adjusting for
CD14 and CRP. The RR (95% CI) of being a routine progressor for
hildren with baseline viral load ≥ 5 log10 copies/ml was 25.2 (8.1
77.7; p <0.0001) and 5.1 (1.6 – 16.0; p =0.006) in those with CRP
3mg/L after adjusting for sCD14. Although mean (SD) sCD14 was
igniﬁcantlyhigher in the routineprogressors versus the LTNP (1.96
0.43) vs 1.66(0.38) million pg/mL; P <0.001), it was not signiﬁcant
n a multivariate model after adjusting for viral load and CRP.fectious Diseases 16S (2012) e158–e316 e193
Conclusion: Baseline HIV RNA ≥ 5 log and CRP ≥ 3mg/L are
independent predictors of faster HIV disease progression rates. HIV
RNA with/without CRP could aid in deciding which children should
start ARV sooner.
http://dx.doi.org/10.1016/j.ijid.2012.05.763
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Susceptibility of HIV-1 CRF01 AE viruses to a CD4-binding site
monoclonal antibody, IgG1 b12
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Background: A human monoclonal antibody, IgG1 b12 (b12)
recognizes a conformational epitope on human immunodeﬁciency
virus type 1 (HIV-1) envelope glycoprotein (Env) gp120 that
overlaps the CD4 binding site. Although b12 is able to broadly
neutralize HIV-1 subtype B, C and D viruses, it poorly neutralizes
most CRF01 AE viruses. In this report, we examined the mecha-
nisms underlying low b12 susceptibility of CRF01 AE viruses, using
recently established CRF01 AE Env (AE-Env)-recombinant viruses.
Methods: AE-Env genes were cloned into the pNL4-3-derived
luciferase reporter proviral construct, pNL-envCT to generate
AE-Env-recombinant viruses. In addition, N-linked glycosylation
mutantswere generated by site-directedmutagenesis. Viral super-
natants were prepared by transfecting 293T cells with the proviral
construct. Then, neutralization susceptibility of the recombinant
viruses to b12 was examined.
Results: We found that two potential N-linked glycosylation
(PNLG) sites, designated as N186 and N197 (amino acid num-
bering is based on HXB2 Env), in the V2 and C2 region of Env
gp120 played an important role in regulating the b12 suscepti-
bility of AE-Env-recombinant viruses. Namely, removal of N186
and/or N197 conferred the b12 susceptibility of 15 resistant AE-
Env-recombinant viruses, whereas the removal of N301, N339,
N386orN392 fromthe remainingb12-resistant viruses fromwhich
N186 and/or N197 had been removed was not sufﬁcient to confer
the b12 susceptibility. Interestingly, the introduction of an aspartic
acid at residue 185 into a resistant virus fromwhichN197 had been
removed, 47CC11-N197Q-G185D, conferred the b12 susceptibility.
In addition, the introduction of D185 into this virus from which
N197 was not removed, 47CC11-G185D, also increased the b12
susceptibility, although the extent of b12 susceptibility was lower
than that of 47CC11-N197Q-G185D. The conservation of D185 in
Subtype B, C and CRF01 AE which obtained from the HIV sequence
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ing in every HCV/HIV co-infected patient. Every LV dysfunction
suspicion should be conﬁrmed by echocardiographic.194 15th ICID Abstracts / International Journa
atabase (n=200) were 74%, 19.5% and 24.5%. Further studies to
larify the mechanism underlying the b12 resistance of CRF01 AE
iruses are ongoing.
Conclusion:Neutralization susceptibility of AE-Env is regulated
y the N-linked glycosylation sites, N186 and N197, in V2 and C2
egions cooperated with amino acid residue 185 in V2 region of
p120.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.764
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n search for a new anti-HIV-1 drug through inhibition of CA-
ypA interaction
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Background: Currently available antiretroviral drugs are clas-
iﬁed into 4 classes including reverse transcriptase inhibitors, pro-
ease inhibitors, integrase inhibitors and entry/fusion inhibitors.
ighly active antiretroviral therapy (HAART), using a combination
f three ormore antiretroviral drugs, canmanageHIV-1 replication
or many years; however, the virus tries to survive under antiretro-
iral therapy by mutate itself to become a drug-resistant variant.
herefore, the development of new classes of anti-HIV-1 drugs
ith different inhibition mechanisms is required. The interaction
etweenHIV-1 capsidprotein (CA) andhumancyclophilinA (CypA)
s crucial for HIV-1 life cycle. Although the role of CypA in HIV-1 life
ycle remains unclear, CA-CypA interaction is an interesting target
or the development of new anti-HIV-1 agents.
Methods: Seventy-seven compounds which could bind to CA
n silico were tested for its activity against HIV-1 replication. Each
ompoundwas tested in vitroat aﬁxconcentrationusingavesicular
tomatitis virus G protein (VSVG)-pseudotyped, luciferase reporter
IV-1 in the 1st round screening. The compounds that showed
otent HIV-1 inhibition were evaluated for dose-dependent effect
nd cytotoxicity effect in the 2ndround screening.
Results: Eleven compounds showed a potent inhibitory effect
n HIV-1 replication in the 1st round screening. Five compounds
ere considered to be safe and potent HIV-1 inhibitors in the 2nd
ound screening.
Conclusion: Although most compounds had little or no effect
n HIV-1 replication, ﬁve compounds showed a potent inhibitory
ctivity on viral replication through our screening. Further studies
n their inhibitory mechanisms are underway.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.765fectious Diseases 16S (2012) e158–e316
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HCV co-infection may promote the subclinical left ventricular
dysfunction development in HIV-infected subjects
M. Dabrowska, T. Mikula, A. Wiercinska-Drapalo ∗
Warsaw Medical University, Warsaw, Poland
Background:ChronicHCV infectionmaybe linkedwithpossible
myocarditis and cardiomyopathy development. The pathophysiol-
ogy of cardiac injury in hepatitis C is still unknown, however it
seems that inﬂammation and apoptosis may play a crucial role in
this progressive process. The brain natriuretic peptide (BNP) is a
hormone secreted predominantly from the cardiac ventricles on
response to increased wall stress, wall distension and stretching
or neurohormonal activation. Presently, BNP is commonly used
as a sensitive biomarker of subclinical/clinical left ventricular (LV)
dysfunction.
The present study aimed to compare BNP serum levels in HIV-
infected and HCV/HIV co-infected subjects with or without ARV
therapy.
Methods: Eighty HIV-infected patients (65 males, 15 females,
mean age 40 years; 29 with HCV co-infection, 48 on cART) were
included to the cross-sectional study. Compensated liver cirrhosis
was diagnosed clinically in 9 (11%) studied subjects, all of them
had HCV/HIV co-infection. One HCV/HIV co-infected subject had
conﬁrmed right ventricular dysfunction diagnosis. The BNP serum
levels were evaluated by ELISA. A BNP cut-off level for heart fail-
ure diagnosis was 100 pg/mL as in immunocompetent population.
In statistical analyses U Mann-Whitney, Spearman correlation and
chi2 tests were used. P <0.05 was considered statistically signiﬁ-
cant.
Results: Seventy eight (97.5%) studied subjects had BNP con-
centration above 42 fmol/L (100 pg/mL), 7 patients (8.7%) had
concentration above 168 fmol/L (400 pg/mL) which is associated
with a worse outcome. There was no difference in mean BNP
serum levels inARV-treated anduntreatedpatients (106.2±94.5 vs
116.4±87.9 fmol/L; p =0.15). However, the mean BNP serum level
was signiﬁcantly higher in HCV/HIV co-infected in comparison to
HIV mono-infected patients (160.0±130.9 vs 81.9±37.2 fmol/L;
p <0.0001). There was no relationship between BNP serum levels
and HIV viral load, CD4 cell count, gender and ABC or PIs use.
Conclusion: HCV co-infection may signiﬁcantly enhance the
risk of the subclinical LV dysfunction in HIV-infected subjects.
The ARV therapy probably does not reduce progressive myocardial
damage in this group of patients. We suggest regular BNP screen-http://dx.doi.org/10.1016/j.ijid.2012.05.766
